Anavex, Glovia, And India Globalization Capital: The Future Of Alzheimer’s Treatments

Summary Anavex 2-73, Glovia’s Feru-guard, and India Globalization Capital’s Hyalolex act as antioxidants which is likely the key to treating Alzheimer’s disease. Glovia is not currently a publicly traded company in the United States; regardless, its natural product holds considerable promise for the treatment of Alzheimer’s disease. India Globalization Capital’s management and products have come under sharp criticism. Results from Anavex’s current Alzheimer’s trial will not be available until March 2021. After each Alzheimer’s drug failure, the inevitable question is always asked what are we doing wrong. Anavex ( AVXL ), Glovia, and India Globalization Capital ( IGC ) are three companies that may have the correct answer. Each company’s drug candidate acts as an antioxidant and this is likely the key to treating Alzheimer’s disease. Following is compelling evidence that oxidation and nitration are the key factors behind the onset and progression of Alzheimer’s disease: The increase in oxidative stress and the decrease in the brain’s main antioxidant glutathione exactly parallels the onset and progression of Alzheimer’s disease ( glutathione depletion and Alzheimer’s disease ). All genetic mutations that lead to early onset of Alzheimer’s disease increase oxidative stress ( genetic mutations and oxidative stress ). Reducing that stress ( genetic mutations and environmental toxins ) and using specific antioxidants may delay the onset of Alzheimer’s disease in these cases by up to ten years. Oxidative stress leads to the formation of amyloid oligomers, hyperphosphorylated tau, and neuroinflammation all of which in turn increase oxidative stress, but without that stress each does relatively little damage to the brain ( amyloid , tau , neuroinflammation ). All of the main features of Alzheimer’s disease are the direct result of oxidation and nitration: mitochondrial dysfunction, DNA damage, the reduced synthesis and release of neurotransmitters needed for the retrieval of short-term […]

Click here to view full article